Portside

TPP's fate in congress is uncertain at best; Long-awaited text reveals gaps between administration claims and actual TPP terms on key congressional, public concerns. Many in Congress said they would support the TPP only if, at a minimum, it included past reforms made to trade pact intellectual property rules affecting access to affordable medicines. But the TPP rolls back that past progress and provides pharmaceutical firms with new monopoly rights for biotech drugs.

Medicine may be on the brink of an enormous public health achievement: turning the tide against hepatitis C, a silent plague that kills more Americans annually than AIDS and is the leading cause of liver transplants. If the effort succeeds, it will be an unusual conquest of a viral epidemic without using a vaccine. But the new drugs are expected to cost from $60,000 to more than $100,000 for a course of treatment. Access could be a problem, particularly for uninsured.